menu
    • menu

    Company profile for Kinaset Therapeutics

    NEW Drugs in Dev: 3
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    At Kinaset Therapeutics, we intend to develop novel respiratory therapeutics that can positively impact people affected by intractable diseases. Our novel lead asset and experienced team combine a potentially best in class approach to treating severe asthma. Founded by serial bioentrepreneur Robert Clarke, Ph.D., with Roger Heerman, MBA, and Frazer Morgan, the executive leadership has over sixty-five combined years of biopharm...
    At Kinaset Therapeutics, we intend to develop novel respiratory therapeutics that can positively impact people affected by intractable diseases. Our novel lead asset and experienced team combine a potentially best in class approach to treating severe asthma. Founded by serial bioentrepreneur Robert Clarke, Ph.D., with Roger Heerman, MBA, and Frazer Morgan, the executive leadership has over sixty-five combined years of biopharma experience and significant expertise in respiratory drug development and commercialization. Company’s lead program is initially focused on the unmet need in eosinophilic.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Kinaset TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    10 Knollwood Road, Medfield, MA 02052, United States
    Telephone
    Telephone
    (508) 858-5810
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.kinasettherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/kinaset-tx/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    EQT Life Sciences Supports Kinaset Therapeutics' $103M Series B
    EQT Life Sciences Supports Kinaset Therapeutics' $103M Series B

    12 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/eqt-life-sciences-backs-kinaset-therapeutics-usd103-million-series-b-to-advance-inhaled-therapeutic-for-treatment-of-respiratory-diseases-302658467.html

    PR NEWSWIRE
    12 Jan 2026
    Share Share
    Kinaset Therapeutics Raises $103M Series B for Inhaled Therapy
    Kinaset Therapeutics Raises $103M Series B for Inhaled Therapy

    10 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260110058494/en/Kinaset-Therapeutics-Announces-%24103-Million-Oversubscribed-Series-B-Financing-to-Advance-Novel-Inhaled-Therapeutic-Candidate-for-Respiratory-Diseases

    BUSINESSWIRE
    10 Jan 2026
    Share Share
    Kinaset’s IND For Frevecitinib (KN-002) In Asthma Cleared By FDA
    Kinaset’s IND For Frevecitinib (KN-002) In Asthma Cleared By FDA

    29 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250129156532/en

    BUSINESSWIRE
    29 Jan 2025
    Share Share
    Kinaset Therapeutics to Share Outcomes from Frevecitinib Phase 1 Clinical Study
    Kinaset Therapeutics to Share Outcomes from Frevecitinib Phase 1 Clinical Study

    04 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240904367252/en

    BUSINESSWIRE
    04 Sep 2024
    Share Share
    Kinaset Debuts Positive KN-002 Phase 1b Outcomes At ATS 2024
    Kinaset Debuts Positive KN-002 Phase 1b Outcomes At ATS 2024

    21 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240521531651/en

    BUSINESSWIRE
    21 May 2024
    Share Share
    Kinaset to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
    Kinaset to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

    21 Dec 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231221190694/en

    BUSINESSWIRE
    21 Dec 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search